EPB41L2抗体;EPB41L2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain using P13326(EPB41L2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The EPB41L2 antibody targets the Erythrocyte Membrane Protein Band 4.1-Like 2 (EPB41L2), also known as 4.1B, a member of the protein 4.1 superfamily involved in linking cell membrane proteins to the cytoskeleton. EPB41L2 plays critical roles in maintaining cell structure, polarity, and adhesion by interacting with transmembrane proteins (e.g., adhesion receptors) and cytoskeletal components via its conserved FERM (Four-point-one, Ezrin, Radixin, Moesin) domain. It is widely expressed in tissues, particularly in the brain, kidney, and epithelial cells.

Research highlights EPB41L2 as a potential tumor suppressor, with its loss or downregulation linked to cancers like gliomas, breast cancer, and lung adenocarcinoma. Dysregulation may contribute to uncontrolled cell proliferation, migration, and metastasis. Antibodies against EPB41L2 are essential tools for studying its expression patterns, subcellular localization, and interactions in normal and pathological states. They are used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to explore its role in cell signaling, epithelial-mesenchymal transition (EMT), and diseases like neurodegenerative disorders (e.g., Alzheimer’s) or cancer progression. Commercial antibodies are typically validated for specificity using knockout controls or epitope tagging. Understanding EPB41L2’s function through antibody-based assays provides insights into its mechanisms in cytoskeletal organization and therapeutic potential.